

# Stevanato Group Extends Pen Injector Technology Licensing Agreement With Haselmeier

*Alina<sup>®</sup> pen injector platform is now available for several new therapeutic areas*

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an extension to its licensing agreement with Haselmeier, a company of the medmix group, for its Axis-D<sup>™</sup> pen injector technology.

This press release features multimedia. View the full release here:

<https://www.businesswire.com/news/home/20220126005327/en/>



(Photo: Business Wire)

The extension gives the company exclusivity to offer the technology to support a broader range of drugs for its biopharma customers beyond diabetes, including therapeutic areas such as obesity, cardiovascular disease, gastrointestinal disorders, pain management, neurological

disorders, arthritis, and others. Stevanato Group is focused on delivering an integrated end-to-end product portfolio, supported by its scientific and analytical processes and services.

Utilizing the Axis-D<sup>™</sup> pen injector technology, Stevanato Group has developed its Alina<sup>®</sup> variable-dose and fixed-dose pen injector platform compatible with established therapeutic regimens as well as innovative drug therapies related to diabetes care.

Franco Moro, Stevanato Group Chief Executive Officer, commented: "The expansion of this agreement is an important step in enhancing and growing the opportunities in our drug delivery systems portfolio as we broaden our capabilities in this key market. We are constantly working with our customers to satisfy their needs, as we continue to experience an increase in demand for our high-value solutions and a shift up of the product value

chain.”

Adam Stops, Head of Product Management for Drug Delivery Systems at Stevanato Group, added: "The Alina<sup>®</sup> pen injector platform combines ease of use for patients with faster time-to-market access for pharma organizations. Our patient-centric solutions aim to improve the lives of patients as they manage their complex health conditions. The extension of our licensing agreement with Haselmeier enables us to offer this innovative technology for use in additional therapeutic areas – helping even more patients – as we continue the expansion of our integrated capabilities in the proprietary drug delivery space.”

Introduced at the recent CPhI Worldwide event in Milan, Alina<sup>®</sup> is an ideal fit for Stevanato Group's integrated approach, which supports pharma companies at every stage of the drug development process – from analytical services and drug containment solutions to automation and assembly equipment, and from proprietary devices to contract manufacturing of devices.

### **About Stevanato Group**

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit [stevanatogroup.com](http://stevanatogroup.com).

### **Legal Notices**

Axis-D is a trademark of Sulzer Mixpac AG (a company of the medmix group)

### **Forward-Looking Statements**

This press release may include forward-looking statements. The words "aim", "opportunities" and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs, or current expectations concerning, among other things, the Company's product offering, the potential use of the Company's products to treat different diseases, growth opportunities, market position, and the expansion of the Company's integrated capabilities. The forward-looking statements in this press release are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance, or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators, and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the

political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20220126005327/en/>

#### **Media**

Stevanato Group

[media@stevanatogroup.com](mailto:media@stevanatogroup.com)

#### **Investor Relations**

Lisa Miles

[lisa.miles@stevanatogroup.com](mailto:lisa.miles@stevanatogroup.com)

Source: Stevanato Group